

Careers at Amgen

A panel discussion in partnership with iJOBS

September 21st 2023

AMGEN



We Serve
Patients
Suffering from
Serious Illness



AMGEN

Our Products Reflect Our Commitment To Serving Patients Living With Serious Illness



27 FDA-approved products on the market for a variety of indications spanning
Oncology, inflammation, bone health, neuroscience, nephrology and cardiovascular disease

Therapeutic areas



ONCOLOGY



INFLAMMATION



GENERAL MEDICINE

We serve millions of seriously ill patients living with cancer, inflammatory diseases, cardiovascular disease and more.



FOUNDED
1980



GLOBAL HQ
Thousand Oaks,
California, USA



EMPLOYEES
25,000+



OF PATIENTS REACHED
~10 million
ANNUALLY



R&D INVESTMENT
\$4.4 billion
IN 2022



DONATIONS
\$2.2 billion*
Through
AMGEN SAFETY NET
FOUNDATION IN 2022



MARKETS
~100




TOTAL REVENUE
\$26.3 billion
IN 2022


*Valued at wholesale acquisition cost.



Organizational structure



Geographical footprint: Amgen R&D/Operations/BD



Global research and manufacturing sites:

- Burnaby (British Columbia, Canada)
- Copenhagen (Denmark)
- Reykjavik (Iceland)
- Dun Laoghaire (Ireland)
- Singapore



Panelist introductions



Andrew Holland, PhD
Director, Precision Oncology



Ngoni Madungwe, PhD
Senior Scientist, Process Development



Bhargava Nemmaru, PhD
Senior Scientist, Process Development
(Co-Moderator)



Juma Bridgewater, PhD
Associate Director, Process
Development



Duncan Huston-Paterson, PhD
Director, Business Development

Andrew Holland, PhD

Director, Precision Oncology



I am in the Precision Oncology Therapeutic Area. Our goal is to identify and validate targets that cancer cells rely on for proliferation and design small molecule therapeutics to interdict these targets.

I was raised and educated in the UK. I moved to the US in 2007 for a postdoctoral fellowship and joined the faculty at Johns Hopkins University School of Medicine in 2013. I joined Amgen in February of this year.

Education:

PhD, University of Manchester (2006)

Employment:

Postdoc, UCSD (2007 – 2013)

Asst Professor – Professor, Johns Hopkins University (2013 – 2023)

Amgen (2023 – Present)



Ngoni Madungwe, PhD

Senior Scientist, Process Development



I am in the Pivotal Biologics Drug Substance group (sub-group in Process Development) focused on upstream cell culture process design and characterization to enable process transfer from lab scale to pilot plant and commercial scale for cell-derived protein therapies.

Education:

PhD, UT Health San Antonio (2020)

Employment:

Vertex Pharmaceuticals (2013 – 2015)

Amgen (2020 – Present)

Juma Bridgewater, PhD

Associate Director, Process Development



I am a scientist in the attribute sciences group. We support the process development of products in the clinic with testing methods that ensure product quality. We also fully characterize our molecules to understand which molecular features need to be controlled during processing and storage.

Education:

PhD, Umass Amherst (2006)

Employment:

Vertex Pharmaceuticals (2006 – 2008)

Abbott (2008 – 2011)

Immunogen (2011 – 2015)

BMS (2015 – 2021)

Amgen (2021 – Present)

Duncan Huston-Paterson, PhD

Director, Business Development



I am part of the Business Development team focused on technologies to enable the next generation of Amgen drugs.

My team identifies innovative technologies and platforms, and then negotiates the business deals to bring them into Amgen.

Education:

PhD, University of Oxford (2015)

Employment:

Integral Molecular (2015 – 2019)

Amgen (2019 – Present)

Bhargava Nemmaru, PhD

Senior Scientist, Process Development



I am in the Pivotal Biologics Drug Substance group (sub-group in Process Development) focused on downstream process design and characterization to enable process transfer from lab scale to pilot plant and commercial scale for protein therapeutics.

Education:

PhD, Rutgers University (2021)

Employment:

Amgen (2021 – Present)